Former head of GSK China is charged with briberyBMJ 2014; 348 doi: https://doi.org/10.1136/bmj.g3356 (Published 16 May 2014) Cite this as: BMJ 2014;348:g3356
- Jane Parry
- 1Hong Kong
Mark Reilly, the former general manager of GlaxoSmithKline’s operations in China, has been charged with corporate bribery, bribing non-government officials, and bribing business units.
The charges are in connection with a scandal that broke in July last year when China’s Public Security Bureau announced that senior Chinese executives of GlaxoSmithKline (China) Investment Co had confessed to widespread bribery and tax crimes.1 The firm was accused of paying up to ¥3bn (£300m; €350m; $490m) to travel agencies as a means to facilitate bribes to doctors, boosting drug sales. Reilly left China when the scandal broke but then returned voluntarily to help with ongoing investigations into the company’s …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial